Business
Ironwood Pharmaceuticals Provides Update on Impact of COVID-19
BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today provided an update on certain impacts of
About this update from Ironwood Pharmaceuticals, Inc.
[{"type":"text","content":" BOSTON--(BUSINESS WIRE)--\nIronwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today provided an update on certain impacts of COVID-19 on its business and the actions it is taking to mitigate the spread of this virus and help protect the safety and well-being of its employees, healthcare providers, patients and broader communities.\n\n\n“In the face of the COVID-19 pandemic, we are taking important steps in an effort to help slow the spread of this virus, prioritize the health and safety of our colleagues and communities, and promote business continuity,” said Mark Mallon, chief executive officer of Ironwood. “Ironwood is focused on our mission of advancing the treatment of GI diseases and redefining the standard of care for millions of patients. We entered 2020 in a strong position and are closely monitoring the COVID-19 situation, evaluating our preparedness, and implementing plans to help address the evolving circumstances in an effort to support the long-term value of our business.”\n\n\nProtecting Ironwood Colleagues and Communities\n\n\nSince March 16, Ironwood employees, including customer-facing employees, have been working remotely. Ironwood has suspended all in-person interactions with customers, including visits to physician offices, clinics and hospitals. Customer-facing employees are providing support virtually through telephone and web-based technologies. Additionally, all work-related travel has been discontinued.\n\n\nIronwood is following guidance from the U.S. Centers for Disease Control and Prevention (CDC) and will continue to assess when it is appropriate for employees to return to normal work practices.\n\n\nMaintaining U.S. LINZESS® (linaclotide) Manufacturing and Supply Chain Continuity\n\n\nIn collaboration with our partner Allergan plc, Ironwood is focused on maintaining the availability of LINZESS for adult patients suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation. As of the date of this press release, COVID-19 has not caused significant disruptions to manufacturing operations nor supply of LINZESS in the U.S. Ironwood and Allergan believe there is sufficient supply of LINZESS on hand to meet U.S. commercial needs at this time and continue to closely monitor the situation.\n\n\nAs a reminder, Ironwood’s ex-U.S. partners ar...